Richard Champlin, MD

home / authors / richard-champlin-md

Articles

Nonmyeloablative Preparative Regimens for Allogeneic Hematopoietic Transplantation

Richard Champlin, MD;Issa F. Khouri, MD;Paolo Anderlini, MD;Marcos J. G. De Lima, MD;Chitra Hosing, MD;John Mcmannis, PhD;Jeffrey Molldrem, MD;Naoto Ueno, MD;Sergio Giralt, MD

January 1st 2003

High-dose myeloablative therapy with allogeneic hematopoietictransplantation is an effective treatment for hematologic malignancies,but this approach is associated with a high risk of complications.The use of relatively nontoxic, nonmyeloablative, or reduced-intensitypreparative regimens still allows engraftment and the generation ofgraft-vs-malignancy effects, is potentially curative for susceptiblemalignancies, and reduces the risk of treatment-related morbidity.Two general strategies along these lines have emerged, based on theuse of (1) immunosuppressive chemotherapeutic drugs, usually apurine analog in combination with an alkylating agent, and (2) lowdosetotal body irradiation, alone or in combination with fludarabine(Fludara).

Reinventing Bone Marrow Transplantation

Richard Champlin, MD;Issa F. Khouri, MD;Stephen Komblau, MD;Jeffrey Molldrem, MD;Sergio Giralt, MD

May 1st 1999

The therapeutic benefit of allogeneic hematopoietic transplantation is due largely to an immune graft-vs-malignancy effect. Most of the evidence for such an effect has come from studies of allogeneic transplantation in